Results 81 to 90 of about 288,299 (272)
Protein O‐glycosylation in the Bacteroidota phylum
FEBS Open Bio, EarlyView.Species of the Bacteroidota phylum exhibit a unique O‐glycosylation system. It modifies noncytoplasmic proteins on a specific amino acid motif with a shared glycan core but a species‐specific outer glycan. A locus of multiple glycosyltransferases responsible for the synthesis of the outer glycan has been identified.
Lonneke Hoffmanns +2 more
wiley +1 more source
Metabolic preconditioning in CD4+ T cells restores inducible immune tolerance in lupus-prone mice
JCI Insight, 2021 Autoimmune disease has presented an insurmountable barrier to restoration of durable immune tolerance. Previous studies indicate that chronic therapy with metabolic inhibitors can reduce autoimmune inflammation, but it remains unknown whether acute ...
Christopher S. Wilson +6 more
doaj +1 more source
mTORC1 Is Not Principally Involved in the Induction of Human Endotoxin Tolerance
Frontiers in Immunology, 2020 Endotoxin tolerance represents a safeguard mechanism for preventing detrimental prolonged inflammation and exaggerated immune/inflammatory responses from innate immune cells to recurrent harmless pathogens.
Kristin Ludwig +3 more
doaj +1 more source
Understanding and Overcoming Immunotherapy Resistance in Skin Cancer: Mechanisms and Strategies
Aging and Cancer, EarlyView.This narrative review explores the mechanisms driving immunotherapy resistance in skin cancer, including tumor microenvironment factors, genetic mutations, and immune evasion strategies. It highlights potential strategies to overcome resistance, offering insights for improving therapeutic outcomes and guiding future research in personalized ...
Shreya Singh Beniwal +8 more
wiley +1 more source
Aging and Cancer, EarlyView.Aging weakens the blood–brain barrier (BBB), increasing susceptibility to CNS cancers and complicating treatment. This review examines BBB deterioration, its impact on drug delivery, and potential interventions like targeting neuroinflammation and advanced therapies.
Quang La, Aiman Baloch, David F. Lo
wiley +1 more source
Detecting Anomalous Process Behaviour using Second Generation Artificial Immune Systems [PDF]
arXiv, 2010 Artificial Immune Systems have been successfully applied to a number of problem domains including fault tolerance and data mining, but have been shown to scale poorly when applied to computer intrusion detec- tion despite the fact that the biological immune system is a very effective anomaly detector.
arxiv
Phase 1, First‐In‐Human, Single‐/Multiple‐Ascending Dose Study of Iluzanebart in Healthy Volunteers
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective To evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of iluzanebart, a fully human monoclonal antibody TREM2 (triggering receptor expressed on myeloid cells 2) agonist, after single‐ (SAD) and multiple‐ascending‐dose (MAD) administration.
Andreas Meier +8 more
wiley +1 more source
Liver-Mediated Adaptive Immune Tolerance
Frontiers in Immunology, 2019 The liver is an immunologically tolerant organ that is uniquely equipped to limit hypersensitivity to food-derived antigens and bacterial products through the portal vein and can feasibly accept liver allografts.
Meijuan Zheng +2 more
doaj +1 more source
A Hybrid Approach Towards Intrusion Detection Based on Artificial Immune System and Soft Computing [PDF]
arXiv, 2012 A number of works in the field of intrusion detection have been based on Artificial Immune System and Soft Computing. Artificial Immune System based approaches attempt to leverage the adaptability, error tolerance, self- monitoring and distributed nature of Human Immune Systems.
arxiv
ADAPT NXT: Fixed Cycles or Every‐Other‐Week IV Efgartigimod in Generalized Myasthenia Gravis
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective This phase 3b, open‐label, randomized ADAPT NXT study investigated the efficacy, safety, and tolerability of efgartigimod administered in either a fixed cycles dosing regimen (3 cycles of 4 once‐weekly infusions, with 4 weeks between cycles) or a cycle followed by every‐other‐week (Q2W) dosing.
Ali A. Habib +16 more
wiley +1 more source